Effects of short-term preoperative intranasal dexmedetomidine plus conventional treatment on delirium following cardiac surgery in patients with sleep disorders.
Jun Fang, Jia Yang, Mingyu Zhai, Qiong Zhang, Min Zhang, Yanhu Xie
{"title":"Effects of short-term preoperative intranasal dexmedetomidine plus conventional treatment on delirium following cardiac surgery in patients with sleep disorders.","authors":"Jun Fang, Jia Yang, Mingyu Zhai, Qiong Zhang, Min Zhang, Yanhu Xie","doi":"10.1186/s13741-024-00371-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Study objectives: </strong>To assess whether preoperative dexmedetomidine (DEX) nasal drips combined with conventional treatment could mitigate the occurrence of postoperative delirium (POD).</p><p><strong>Design: </strong>A prospective randomised controlled study.</p><p><strong>Setting: </strong>The cardiac surgery intensive care unit (CSICU) and patient hospitalisation ward at a university hospital.</p><p><strong>Participants: </strong>A total of 100 patients (aged ≥60 years) undergoing cardiac surgery at a university hospital between 7 January 2022, and 30 November 2022 met the eligibility criteria and were included in the study.</p><p><strong>Interventions: </strong>Patients with sleep disorders (Pittsburgh Sleep Quality Index ≥8) were divided into two groups: Group A (the placebo group, n=50), receiving a short-term preoperative placebo combined with conventional treatment and Group B (the DEX group, n=50), receiving short-term preoperative DEX combined with conventional treatment.</p><p><strong>Measurements and results: </strong>The Confusion Assessment Method for the ICU (CAM-ICU) was used for POD assessment in the CSICU, while the CAM was employed to assess delirium in the patient ward. Group B demonstrated a reduced incidence of POD compared to Group A (12% vs. 30%, odds ratio: 0.318, 95% confidence interval: 0.112-0.905, p=0.027).</p><p><strong>Conclusion: </strong>The combined treatment involving DEX demonstrated a decreased incidence of POD in elderly individuals with sleep disorders undergoing cardiac surgery compared to the placebo combination treatment.</p><p><strong>Trial registration: </strong>URL: www.chictr.org.cn with registration number ChiCTR 2100043968, registered on 06/03/2021.</p>","PeriodicalId":19764,"journal":{"name":"Perioperative Medicine","volume":"13 1","pages":"17"},"PeriodicalIF":2.0000,"publicationDate":"2024-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10924345/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Perioperative Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13741-024-00371-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ANESTHESIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Study objectives: To assess whether preoperative dexmedetomidine (DEX) nasal drips combined with conventional treatment could mitigate the occurrence of postoperative delirium (POD).
Design: A prospective randomised controlled study.
Setting: The cardiac surgery intensive care unit (CSICU) and patient hospitalisation ward at a university hospital.
Participants: A total of 100 patients (aged ≥60 years) undergoing cardiac surgery at a university hospital between 7 January 2022, and 30 November 2022 met the eligibility criteria and were included in the study.
Interventions: Patients with sleep disorders (Pittsburgh Sleep Quality Index ≥8) were divided into two groups: Group A (the placebo group, n=50), receiving a short-term preoperative placebo combined with conventional treatment and Group B (the DEX group, n=50), receiving short-term preoperative DEX combined with conventional treatment.
Measurements and results: The Confusion Assessment Method for the ICU (CAM-ICU) was used for POD assessment in the CSICU, while the CAM was employed to assess delirium in the patient ward. Group B demonstrated a reduced incidence of POD compared to Group A (12% vs. 30%, odds ratio: 0.318, 95% confidence interval: 0.112-0.905, p=0.027).
Conclusion: The combined treatment involving DEX demonstrated a decreased incidence of POD in elderly individuals with sleep disorders undergoing cardiac surgery compared to the placebo combination treatment.
Trial registration: URL: www.chictr.org.cn with registration number ChiCTR 2100043968, registered on 06/03/2021.
研究目的评估术前右美托咪定(DEX)滴鼻与常规治疗相结合能否减轻术后谵妄(POD)的发生:前瞻性随机对照研究:地点:一所大学医院的心脏外科重症监护室(CSICU)和患者住院病房:2022年1月7日至2022年11月30日期间在某大学附属医院接受心脏手术的100名患者(年龄≥60岁)符合资格标准并纳入研究:睡眠障碍患者(匹兹堡睡眠质量指数≥8)分为两组:A组(安慰剂组,n=50),接受术前短期安慰剂联合常规治疗;B组(DEX组,n=50),接受术前短期DEX联合常规治疗:CSICU病房采用重症监护室意识障碍评估法(CAM-ICU)进行POD评估,病房则采用重症监护室意识障碍评估法进行谵妄评估。与A组相比,B组的POD发生率较低(12% vs. 30%,几率比:0.318,95%置信区间:0.112-0.905,P=0.027):结论:与安慰剂联合治疗相比,DEX联合治疗可降低接受心脏手术的老年睡眠障碍患者的POD发生率:网址:www.chictr.org.cn,注册号为ChiCTR 2100043968,注册日期为2021年3月6日。